Val Saraiba (@valsarb) header
Val Saraiba (@valsarb) profile picture

@emcs_tecdemty md’25 | Former research intern @incanmx | Postdoc research fellow at @MDAndersonNews 🧫| op = own |

Joined February 2020
Photo by Val Saraiba (@valsarb)Photo by Val Saraiba (@valsarb)Photo by Val Saraiba (@valsarb)Photo by Val Saraiba (@valsarb)Photo by Val Saraiba (@valsarb)Photo by Val Saraiba (@valsarb)Photo by Val Saraiba (@valsarb)Photo by Val Saraiba (@valsarb)Photo by Val Saraiba (@valsarb)Photo by Val Saraiba (@valsarb)
Check it out!!! 😁😁😁
Our paper, co-led with @kevanchu in the @dow_lab, is out today in @Cancer_Cell. We analyzed pre-treatment, on-treatment, and post-progression biopsies from 12 CRC patients treated with KRASi + EGFRi. authors.elsevier.com/c/1n8Il…
1
379
Val Saraiba retweeted
ADHD is a neurodevelopmental disorder characterized by symptoms of inattention or hyperactivity–impulsivity. Although it has long been considered to be a childhood-limited condition, follow-up studies have shown a persistent course into adulthood. Learn more: nej.md/4s25aNL
7
58
8
226
35,859
Val Saraiba retweeted
The 2026 #NobelPrize laureates in physiology or medicine have laid the foundation of a new era in neuroscience. Using optogenetics, researchers have been able to reveal neural circuits governing specific memories, feelings, and behaviours relevant for neurological and psychiatric disorders. In clinical medicine, researchers are using the method in attempts to restore sight in people with visual impairment. Optogenetics has fundamentally altered our understanding of the brain. Every day brings new discoveries, helping to solve one of humanity’s great mysteries: how our incredible brain works.
56
1,114
99
2,837
158,751
bioRxiv has a dedicated section for negative results. Use it. Share negative results. Your colleagues will appreciate it.
19
174
12
891
39,887
Hot off the press @Hemasphere_EHA! Happy to share our work identifying CD20 (MS4A1) mutations as a potential resistance mechanism in Waldenström macroglobulinemia, with particular relevance as CD20-targeted therapies, including bispecifics and CAR-T cells, enter the field.
4
3
21
1,050
El @TecdeMonterrey fue seleccionado por @Forbes USA entre las 15 mejores universidades internacionales para estudiantes de Estados Unidos, junto con @UniofOxford, @Cambridge_Uni, @mcgillu, @sciencespo, @Unibocconi, @waseda_univ y la @HKUniversity, entre otras. La nota destaca nuestra acreditación por la asociación estadounidense SACSCOC desde 1950, nuestra oferta en inglés y nuestros programas académicos de ingeniería, tecnología y negocios, entre otras. Gracias a nuestra comunidad del Tecnológico de Monterrey quienes hacen esto posible. 🔗 Ver nota aquí: tec.rs/forbestop
10
182
13
625
23,604
Val Saraiba retweeted
Magic hands and getting experiments to work involve, of course, mental habits. A fanatical attention to the physical details, more so than in a complex kitchen recipe, is critical. But so is believing the outcome of a failed experiment, rather than assuming you just screwed up.
Many thanks to @carlzimmer at the @nytimes for spending so much time with us and capturing the "magic" of science so beautifully. "Success can be just as mysterious as failure. Some researchers consistently get experiments to work, earning befuddled admiration from colleagues. Scientists even have a special term for this gift: magic hands. The idea may come as a surprise to people who don’t spend their lives in labs. Science is not supposed to be magic. When scientists carry out experiments, they keep careful records, both in lab notebooks and later in published scientific papers. Other researchers use that information to repeat the experiment. But every scientist discovers sooner or later that essential knowledge is not necessarily written down."
3
4
1
31
2,941
Val Saraiba retweeted
Many thanks to @carlzimmer at the @nytimes for spending so much time with us and capturing the "magic" of science so beautifully. "Success can be just as mysterious as failure. Some researchers consistently get experiments to work, earning befuddled admiration from colleagues. Scientists even have a special term for this gift: magic hands. The idea may come as a surprise to people who don’t spend their lives in labs. Science is not supposed to be magic. When scientists carry out experiments, they keep careful records, both in lab notebooks and later in published scientific papers. Other researchers use that information to repeat the experiment. But every scientist discovers sooner or later that essential knowledge is not necessarily written down."
7
49
29
357
186,249
Val Saraiba retweeted
At 135 days between data and approval, daraxonrasib for pancreas cancer becomes the fastest FDA-approval of the year - by far.
8
46
10
282
71,535
Multiple-hobby girl, from illustration, writing, embroidery, and photography to lab work (yes, my job is my hobby too). 🙂‍↕️🙂‍↕️🙂‍↕️
4
315
Val Saraiba retweeted
📝 JAMA Review: #LiquidBiopsy using circulating tumor DNA can help guide care in #Cancer by identifying gene variants associated with treatment selection, monitoring treatment response, and detecting minimal residual disease after therapy. ja.ma/4z9wOeI
10
1
54
10,028
Val Saraiba retweeted
Today in @NatureBiotech we report OptiPrime, a mechanism-based machine learning model for predicting prime editing (PE) efficiencies and suggesting pegRNAs to achieve a user-specified edit. OptiPrime incorporates biochemical knowledge about PE into its mathematical structure, enabling training on ~300,000 PE efficiencies collected using 40 experimental conditions in multiple labs, and outcome predictions of PE variants such as twin prime editing not used in its training. OptiPrime enabled the rapid identification of efficient PE strategies across a variety of applications in vitro and in vivo, and could outperform months or years of manual experimental optimization. Try out OptiPrime here: optipri.me PDF: drive.google.com/file/d/13JZ… 1/15
7
114
14
439
76,754
Val Saraiba retweeted
Congratulations to the @RevMedicines & @break_cancer KRAS team for this collaboration in @NatureMedicine: Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in #PancreaticCancer nature.com/articles/s41591-0…
5
72
6
216
22,502
Journal Club-133 @Nature #KRAS 変異上皮細胞がamphiregulin (AREG)–EGFRシグナルを介して #線維芽細胞 を線維化型へ再プログラムし、その線維芽細胞が肺胞マクロファージを腫瘍支持的な状態へ変化させ、自己増強型の初期 #TME を形成する。腫瘍発生初期のニッチ形成が、腫瘍細胞単独ではなく、間質細胞との相互作用によって駆動されることを示した研究。 担当:和泉拓野 @Takuya__izumi nature.com/articles/s41586-0…
11
31
4,752
Val Saraiba retweeted
3 papers in @Nature today reflecting large scale efforts at mapping dependencies and multimodal molecular profiling data from a large panel of patient-derived 3D cancer models. This is DepMap on steroids! nature.com/articles/s41586-0… nature.com/articles/s41586-0… nature.com/articles/s41586-0…
3
85
3
323
44,849
Desde la #EMCS celebramos que el talento del @TecdeMonterrey lleve la innovación mexicana a escenarios globales. 🌎 HERA, un sistema de cuidado para personas mayores, fue presentado como finalista en el Harvard Health Systems Innovation Lab @HarvardHS demostrando cómo el emprendimiento puede transformar la atención en salud. 👏🩺 Lee la nota en @ConectaTECmx conecta.tec.mx/es/noticias/n…
1
221
Val Saraiba retweeted
Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) nej.md/4nWaxvM Editorial: Breaking the RAS Barrier in Pancreatic Cancer nej.md/4b67lIM #Oncology
2
79
6
271
67,569
People who don't follow cancer research often ask me why we haven't cured cancer. That perception masks a wonderful reality: We make amazing, stepwise progress every year, and the result is that many people live much longer today than they would have previously. Right now we're in the thick of the annual meeting of the American Society of Clinical Oncology, the biggest research meeting on new cancer medicines, and this morning a bunch of really important studies dropped. I'm going to review them here. This first image is the result for daraxonrasib, a treatment for pancreatic cancer that is generating consdirable excitement. The green line is the probability of living for patients who got the new drug; the gray one is the chemo control group. If you follow cancer drugs, a chart like this will make your breath hitch a little. I'm going to review these and some other data here.
44
425
38
2,297
296,009
Val Saraiba retweeted
Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) nej.md/4nWaxvM #ASCO26 | @ASCO
8
345
29
1,191
73,087
7yr CROWN update of 1L lorlatinib 55% progression-free at 7 YEARS. Median PFS STILL not reached. In metastatic solid tumors, this is essentially unheard of. Let that sink in. And hopefully, one day, this becomes the standard (or even better) for ALL metastatic cancers.#ASCO26 – at Chicago, IL
6
74
14
325
230,890